The United States is falling behind in a critical manufacturing shift that directly impacts its ability to produce essential goods. An estimated 70% of global biomanufacturing capacity for next-generation products is in China, while the U.S. is closer to 10%. This creates growing risk across healthcare, agriculture, and national supply chains, especially during periods of disruption.

Building more facilities alone will not solve the problem. It is slow, capital intensive, and does not address core inefficiencies. In times of war or geopolitical conflict, access to global feedstocks can be disrupted, delaying or halting the production of critical medicines and materials. Economic downturns further strain these systems by reducing workforce stability, limiting capital for operations, and slowing production timelines. Current biomanufacturing systems rely on these fragile global inputs, making them vulnerable when reliability matters most. To compete, the U.S. must increase output from existing infrastructure and localize supply chains around domestic inputs. This requires better production organisms and faster, more predictable scale up.

Without these improvements, the U.S. will remain dependent on foreign manufacturing for critical products. This leaves critical supply chains exposed during geopolitical conflict and economic disruption.

1. Two separate $200k contracts with CyanoCapture to enhance GLP-1 and insulin production
2. $100k LOI with De Novo Foodlabs
3. $200k DOE-funded collaboration with Lawrence Berkeley National Laboratories, Sandia National Laboratories, and Advanced Biofuels Process Development Unit (ABPDU)
4. Partnership with Growth Curve Bio (GCB) to serve clients scaling up agricultural products
5. Partnership with Research Triangle Institute (RTI) to localized supply chains in North Carolina